Skip to main content


Hypoxia and Tumors

Hypoxia and Tumors © royaltystockphoto / FotoliaGuest Editors: Gabriella D’Orazi1, Donatella Del Bufalo& Maria Carla Bosco3

1 - University “G. D’Annunzio”, Chieti, Italy
2 - IRCCS Regina Elena National Cancer Institute, Rome, Italy
3 - IRCCS Giannina Gaslini Institute, Genova, Italy

Submission deadline: 30th June 2020. Submit your research here.

Human solid tumors are invariably less well-oxygenated than the normal tissues from which they arose. The cellular response to insufficient tissue oxygenation, or hypoxia, is mainly mediated by the hypoxia-inducible factor (HIF) family of transcription factors. These regulate the expression of multiple genes involved in processes that drive the adaptation and progression of cancer cells, as suggested by experimental and clinical data form various tumor types. 

Hypoxia leads to resistance to radiotherapy and anticancer chemotherapy, increases angiogenesis and vasculogenesis predisposing to tumor metastases, and contributes to altered metabolism and genomic instability. Tumor hypoxia profoundly changes the interaction and cross-talk of cancer cells with the surrounding tumor microenvironment, leading also to immune-resistance and immune-suppression, which help tumor cells to escape from immune surveillance. 

Therefore, given its central role in tumor progression and resistance to therapies, tumor hypoxia is considered a valid target to be exploited in oncology. Several approaches for targeting hypoxic tumor cells have been proposed in recent years, including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR (unfolded protein response) pathways. Better understanding of hypoxic phenomenon and dissecting out the hypoxia-inducible responses and signaling pathways will grant numerous novel targets in the near future.

The purpose of this thematic series, published in Journal of Experimental & Clinical Cancer Research, is to highlight significant findings and advances in our understanding of the role of the tumor hypoxia in cancer biology and therapy, in light of the 2019 Nobel Prize in Medicine awarded to William G. Kaelin Jr., Sir Peter J. Radcliff and Gregg G. Semenza, whose discoveries contributed to a great understanding to the cell adaptation to reduced oxygen availability.

Keywords: Hypoxia, HIF, Angiogenesis, Invasion and Metastasis, Cancer Stem Cells, Immune response, Metabolic reprogramming, Microenvironment, Innovative therapies. 

The Special Issue will accept Research Articles and Reviews regarding the latest highlights on the role of hypoxia in all aspects of tumor progression, including therapy resistance and metastases. Please note that all manuscripts submitted to this series, will undergo the standard procedure of external peer review.

  1. We have previously described CLDN6 as a tumor suppressor gene in breast cancer. Here, a new finding is that CLDN6 was upregulated under hypoxia, a commonly recognized factor that promotes tumor metastasis. In ...

    Authors: Yiyang Jia, Yantong Guo, Qiu Jin, Huinan Qu, Da Qi, Peiye Song, Xiaoli Zhang, Xinqi Wang, Wenhong Xu, Yuan Dong, Yingying Liang and Chengshi Quan

    Citation: Journal of Experimental & Clinical Cancer Research 2020 39:42

    Content type: Research

    Published on:

  2. Hypoxia is a classic characteristic of the tumor microenvironment with a significant impact on cancer progression and therapeutic response. Hypoxia-inducible factor-1 alpha (HIF-1α), the most important transcr...

    Authors: Xiafeng Peng, Han Gao, Rui Xu, Huiyu Wang, Jie Mei and Chaoying Liu

    Citation: Journal of Experimental & Clinical Cancer Research 2020 39:27

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2020 39:45

  3. Low oxygen condition (hypoxia) is considered a hallmark of rapidly growing solid tumors. The presence of hypoxia renders tumor cells resistant to conventional chemo- and radio-therapy selecting a more malignan...

    Authors: Maria Carla Bosco, Gabriella D’Orazi and Donatella Del Bufalo

    Citation: Journal of Experimental & Clinical Cancer Research 2020 39:8

    Content type: Commentary

    Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2020 39:43